Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C

    Hepatitis C virus (HCV) is chiefly transmitted by blood-to-blood contact. When the blood of a person with hepatitis C enters the bloodstream of another person,...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1
  • Hepatitis C treatment

    Deciding on the best time to take treatment for hepatitis C is not straightforward.It’s important to get support and advice to help you with this...

    From: The basics

    Information level Level 1
  • Hepatitis C virus treatment

    The current preferred treatment regimen for HCV infection is a combination of peginterferon alfa (given by injection) plus ribavirin (given orally). Interferons are human proteins that...

    From: HIV treatments directory

    Information level Level 4
  • Treatment for hepatitis C

    Treatments are available for hepatitis C and aim to cure the condition. People with HIV who are newly diagnosed with hepatitis C should consider the pros and...

    From: Booklets

    Information level Level 2

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Gilead's Harvoni gains NICE yes - but won't face funding delay

    Gilead's next generation hepatitis C pill Harvoni is set to be backed by NICE - and this time NHS England won't be delaying its funding as it has done with the firm's other hep C drug Sovaldi.

    23 hours ago | PM Live
  • Delay HCV Tx and Watch Patients Die

    Delaying hepatitis C (HCV) treatment in patients who also have HIV increases the risk of liver complications and death even if the therapy is successful, a researcher said.

    02 March 2015 | MedPage Today
  • Doctor Panel to Weigh Hepatitis C Drugs’ Costs in Guidelines

    An influential advisory panel of doctors and health experts will for the first time address the cost-effectiveness of pricey hepatitis C drugs in updated guidelines that may change prescribing and coverage for the medicines.

    02 March 2015 | Bloomberg
  • NICE guidance recommends sofosbuvir (Sovaldi, Gilead Sciences) and simeprevir (Olysio, Janssen) for treating hepatitis C

    Following a request from NHS England and consultation with stakeholders, the period during which NHS England has to comply with the recommendations for sofosbuvir is extended to 31 July 2015. The period during which NHS England has to comply with the recommendations for simeprevir has not been extended.

    26 February 2015 | NICE press release
  • Cost-Effectiveness of Immediate Hepatitis C Treatment in Early Disease Analyzed

    For patients with hepatitis C virus (HCV), immediate treatment seems to be cost-effective in those with moderate and advanced fibrosis, and can be cost-effective in patients with no or minimal fibrosis, according to a study published online Feb. 11 in Hepatology.

    20 February 2015 | HCP Live
  • amfAR Report Examines Controversial Pricing of Hepatitis C Treatment

    The new amfAR report, titled “Hepatitis C and Drug Pricing: The Need for a Better Balance,” urges structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge exorbitant prices for their products, however effective they may be.

    19 February 2015 | amfAR
  • The Drug That Is Bankrupting America

    With a rational U.S. drug pricing system, private investors would expect to earn a reasonable multiple of their R&D for a highly successful drug, perhaps even 5 to 10 times the R&D outlays, in order to reflect the long time horizons and high uncertainties surrounding drug development. Yet at a treatment course of $84,000, the multiple for Sovaldi looks to be around 40 times or more.

    18 February 2015 | Huffington Post
  • Healthcare: The race to cure rising drug costs

    The controversy over hepatitis C drug prices has highlighted the broader question of whether pharmaceutical companies can defend their premium pricing model in the world’s biggest healthcare market. It is a battle that big pharma risks losing, raising questions over the economic model of an industry that relies heavily on US profits to reward investors and finance new drugs.

    13 February 2015 | Financial Times
  • UNITAID: 2015 Hepatitis C medicines technology and market landscape

    This report takes stock of a rapidly changing market, where new products have the potential to become “blockbusters” almost overnight – but also risk becoming quickly outdated due to superior products entering the market.

    13 February 2015 | UNITAID
  • Gilead agrees 41,000 euro hep-C drug price for 12 week treatment in Germany

    Drugmaker Gilead has agreed on a price for its hepatitis C drug Sovaldi of 41,000 euros ($46,625) for a 12-week treatment for Germany's statutory medical insurers, the GKV association of Germany's statutory medical insurers said.

    13 February 2015 | Reuters
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.